SHAUN HAWKINS

Shaun is a Managing Partner at Pier 70 and is responsible for managing investments and building the portfolio with particular consideration for the technology and innovation needs in the healthtech area. Shaun has more than 20-years of experience making investments and closing successful deals in healthcare and life sciences spaces. The architect of multiple strategic investment syndicates and startups, Shaun has worked extensively to accelerate the development of early-state innovation.

Shaun is founder of Prosyte Companies, which includes Auxigen Health (US) and Auxigen Medical (US). He continues to serve as a Managing Partners for the group.

Previously, Shaun was Vice President of New Ventures and Private Equity at Eli Lilly and Company. He was responsible for the company’s life science venture capital, private equity, and venture formation activities. In this role he co-created the Capital Funds Portfolio, a $450 million portfolio of funds and new vehicles resulting in a capital efficient strategy for new investments in disruptive innovations. This work led to the launch of new life science private equity funding vehicles in Asia, Canada, Europe and the US.

Earlier, Shaun served in advisory roles for Epidarex Capital, TVM Life Sciences, and Carrick Therapeutics. Previous board service includes directorships with Ivesque, Inc., Accelerator Corp., Audion Therapeutics, Immuneworks Inc., and Zymeworks Inc.

Shaun received his bachelor’s degree from University of Tennessee and his MBA from the Kellogg School of Management at Northwestern University.